Business Wire

ZITADEL

10.6.2022 11:50:09 CEST | Business Wire | Press release

Share
ZITADEL Secures $2.5M to Enhance its Developer-First, Open-Source Identity Management Platform

ZITADEL, innovator of a transformative identity management platform, announces $2.5M in seed funding led by Nexus Venture Partners. The funding will help ZITADEL provide developers with a much-needed open-source alternative for their identity management needs and evolve its solution, scale sales growth, and nurture the open-source community. The current market landscape consists of established but closed-source players, including Auth0, Okta, Firebase, AWS Cognito, and others.

ZITADEL’s founding vision was based on the creation of a streamlined, cloud-native identity management platform to speed time-to-market for software projects. Focused on the simplicity of integration, ready-to-use self-service features, a customizable and secure login with first-class support for passwordless authentication, and an API-first strategy, ZITADEL’s unique turnkey platform offers developers unprecedented flexibility.

Developers often spend countless hours creating, configuring, and operating complex authentication and authorization systems. ZITADEL, which is built mainly in the Go programming language, solves these problems with easy-to-use integrations in multiple languages and frameworks. This flexibility enables developers to utilize prebuilt features provided by ZITADEL to dramatically improve their productivity. In addition, ZITADEL’s capabilities address existing open-source projects which were not built for a cloud-native and serverless environment.

The ZITADEL team is working towards further enriching the solution’s enterprise-readiness. New capabilities include multi-tenancy, unlimited audit trails, improved ability to self-host, and support for serverless deployments, plus the potential to extend ZITADEL’s breadth with custom code created in WebAssembly. Combined with its cloud-native architecture, ZITADEL’s self-hosting capabilities allow privacy-focused customers to own and control their data by running a dedicated version. ZITADEL’s flexible model, with its span of smart efficiency enhancements, is already the go-to solution for numerous marquee enterprise customers.

The generous free tier of ZITADEL’s cloud-hosted offering allows anybody to create a ZITADEL instance in under five minutes—without a credit card. In its ongoing commitment to deliver GDPR support to its customers, ZITADEL Cloud also provides the capability to define the country or geopolitical region in which to store their data.

“Amidst today's complex software projects, ZITADEL provides a turnkey solution that allows developers to get started easily with a secure login, user management, multi-factor authentication, social logins, authorization management, and great APIs. With ZITADEL, we provide an important component to improve the overall security of a project while reducing your time-to-market,” said ZITADEL Co-Founder and CEO, Florian Forster.

“We’re delighted to break new ground partnering with Florian and the ZITADEL team, our first-ever investment in a Swiss company. We believe the future of digital identities is passwordless. ZITADEL takes a developer-first, open-source approach to solving identity management. Its simple and easy-to-integrate building blocks help developers build secure authentication into their applications without requiring deep in-house expertise and resource commitment.” said Abhishek Sharma, Managing Director at Nexus Venture Partners. “ZITADEL is the latest addition to the Nexus family of over a dozen marquee commercial open-source companies,” added Sharma.

About ZITADEL

ZITADEL is the modern open* alternative for Auth0, Firebase Auth, and AWS Cognito, as well as Keycloak, built for the container and serverless era. It provides customers a wide range of out-of-the-box features, including secure login, self-service, OpenID Connect, OAuth2.x, SAML2, branding, Passwordless with FIDO2, OTP, U2F, and an unlimited audit trail to improve the life of developers and developers. With its legal incorporation in Switzerland, ZITADEL is in the unique position of providing its cloud services even to customers with the strictest GDPR requirements. For more information visit https://zitadel.com , follow @zitadel on Twitter, or star the repository https://github.com/zitadel/zitadel on GitHub

About Nexus Venture Partners

Nexus Venture Partners is an early-stage venture capital firm partnering with extraordinary entrepreneurs to help build product-first software companies. With $2 billion under management, Nexus operates as one team across the U.S. and India. The Nexus portfolio includes Apollo.io, Aryaka, Clover Health, Delhivery, Druva, FingerprintJS, Hasura, H2O.ai, Infra Market, Kaltura, MinIO, Observe.ai, Postman, Pubmatic, Quizizz, Rancher, Rapido, Sibros, TileDB, Turtlemint, Unacademy, WhitehatJr, and Zepto. For more information, visit www.nexusvp.com or follow @nexusvp on Twitter.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye